We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Dong-A ST

News List

Intas enters into agreement with Meiji and Dong-A ST to commercialise DMB-3115 expresspharma
July 23, 2021
Under the terms of the agreement, Intas has been granted exclusive licence rights to commercialise DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia.
Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab) prnasia
July 22, 2021
Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement with Meiji and Dong-A Socio Holdings (a parent company of Dong-A ST) to commercialize ...
Dong-A ST and Beactica Therapeutics Achieve Key Milestone in Their Collaboration to Develop New Cancer Treatments biopharmadive
December 10, 2019
Dong-A ST Co., Ltd. (170900: Korea SE), a Korean pharmaceutical company...